Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apidra approved for paediatric use in the US

This article was originally published in Scrip

Executive Summary

The US FDAhas approvedSanofi-Aventis's rapid-acting insulin analogue Apidra (insulin glulisine) for improving glycaemic control in children four years and older with diabetes mellitus. Apidra is already available in the US for use in adults with types 1 and 2 diabetes. The expanded approval was based on data from a 26-week, Phase III open-label, active-control study in 572 children and adolescents aged over four years with type 1 diabetes. Other rapid-acting insulins already approved for use in children in the US include Lilly's Humulin R and Novo Nordisk's Novolog (insulin aspart). Apidra was approved in the EU in July for use in children aged six years and older (Scrip Online, July 28th, 2008).

You may also be interested in...



mRNA Vaccines – Trials Line Up Against Coronavirus

The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.

Novartis Close To EU Approval For Zolgensma At Last

Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.

mRNA Vaccines – A Novel Weapon Against Coronavirus

The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.

Topics

Related Companies

UsernamePublicRestriction

Register

SC030476

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel